Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Plasma cell 1Breast 1

Conditions

Neoplasms 1Immunoglobulin Light-chain Amyloidosis 1Essential Hypertension 1Breast Neoplasms 1

Interventions

Cisplatin 3202Cyclophosphamide 3195Carboplatin 2977Radiotherapy 2790Paclitaxel 2718Gemcitabine 2572pembrolizumab 2384Bevacizumab 2209Docetaxel 2199Fluorouracil 1851Capecitabine 1831Oxaliplatin 1742Dexamethasone 1605Nivolumab 1581Doxorubicin 1501Rituximab 1488Magnetic Resonance Spectroscopy 1387Etoposide 1346Irinotecan 1248Leucovorin 1226Drug Therapy 1205Cytarabine 1130Pemetrexed 1076fludarabine 1063Specimen Handling 1016Vincristine 964Cetuximab 945Trastuzumab 944Prednisone 941Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Diuretics × Clear all
NCT05972785 2024-08-21

Long-term Use of CCB and Breast Cancer Risk

Curtin University

Active not recruiting
68,500 enrolled
Breast

Essential Hypertension, Breast Neoplasms

NCT01511263 2018-03-21

EpiCardiAL

Fondazione IRCCS Policlinico San Matteo di Pavia

Phase 2 Terminated
86 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT02215733 2014-08-13

The Use of Angiotensin Receptor Blockers and the Risk of Cancer

Boehringer Ingelheim

Completed
1,165,781 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡